Your browser doesn't support javascript.
loading
Thrombopoietin Receptor Agonists for Severe Thrombocytopenia after Allogeneic Stem Cell Transplantation: Experience of the Spanish Group of Hematopoietic Stem Cell Transplant.
Bento, Leyre; Bastida, José María; García-Cadenas, Irene; García-Torres, Estefania; Rivera, Daniel; Bosch-Vilaseca, Anna; De Miguel, Carlos; Martínez-Muñoz, María Esther; Fernández-Avilés, Francesc; Roldán, Elisa; Chinea, Anabelle; Yáñez, Lucrecia; Zudaire, Teresa; Vaz, Carlos Pinho; Espigado, Ildefonso; López, Javier; Valcárcel, David; Duarte, Rafael; Cabrera, Rafael; Herrera, Concepción; González-Porras, José Ramón; Gutiérrez, Antonio; Solano, Carlos; Sampol, Antonia.
Afiliación
  • Bento L; Hematology Department, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Islas Baleares, Palma de Mallorca, Spain. Electronic address: leyre.bento@ssib.es.
  • Bastida JM; Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain.
  • García-Cadenas I; Hematology Department, Hospital Sant Creu i Sant Pau, Barcelona, Spain.
  • García-Torres E; Hematology Department, Hospital Universitario Reina Sofía, Córdoba, Spain.
  • Rivera D; Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain.
  • Bosch-Vilaseca A; Hematology Department, Hospital Sant Creu i Sant Pau, Barcelona, Spain.
  • De Miguel C; Hematology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
  • Martínez-Muñoz ME; Hematology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
  • Fernández-Avilés F; Hematology Department, Hospital Clínic de Barcelona, Barcelona, Spain.
  • Roldán E; Hematology Department, Hospital Vall D'hebron, Barcelona, Spain.
  • Chinea A; Hematology Department, Hospital Ramón y Cajal, Madrid, Spain.
  • Yáñez L; Hematology Department, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
  • Zudaire T; Hematology Department, Complejo Hospitalario de Navarra, Pamplona, Spain.
  • Vaz CP; Hematology Department, Instituto Português de Oncologia, Oporto, Spain.
  • Espigado I; Hematology Department, Hospital Virgen del Rocío, Sevilla, Spain.
  • López J; Hematology Department, Hospital Ramón y Cajal, Madrid, Spain.
  • Valcárcel D; Hematology Department, Hospital Vall D'hebron, Barcelona, Spain.
  • Duarte R; Hematology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
  • Cabrera R; Hematology Department, Hospital Universitario Puerta de Hierro, Madrid, Spain.
  • Herrera C; Hematology Department, Hospital Universitario Reina Sofía, Córdoba, Spain.
  • González-Porras JR; Hematology Department, Hospital Universitario de Salamanca, Salamanca, Spain.
  • Gutiérrez A; Hematology Department, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Islas Baleares, Palma de Mallorca, Spain.
  • Solano C; Hospital Clínico de Valencia, Valencia, Spain.
  • Sampol A; Hematology Department, Hospital Universitario Son Espases, Instituto de Investigación Sanitaria Islas Baleares, Palma de Mallorca, Spain.
Biol Blood Marrow Transplant ; 25(9): 1825-1831, 2019 09.
Article en En | MEDLINE | ID: mdl-31152794
ABSTRACT
Persistent thrombocytopenia is a common complication after allogeneic hematopoietic stem cell transplantation (allo-SCT). Romiplostim and eltrombopag are the currently available thrombopoietin receptor agonists (TPO-RAs), and some studies with very small numbers of cases have reported their potential efficacy in the allo-SCT setting. The present retrospective study evaluated the safety and efficacy of TPO-RAs in 86 patients with persistent thrombocytopenia after allo-HSCT. Sixteen patients (19%) had isolated thrombocytopenia (PT), and 71 (82%) had secondary failure of platelet recovery (SFPR). TPO-RA therapy was started at a median of 127 days (range, 27 to 1177 days) after allo-SCT. The median initial and maximum administered doses were 50 mg/day (range, 25 to 150 mg/day) and 75 mg/day (range, 25 to 150 mg/day), respectively, for eltrombopag and 1 µg/kg (range, 1 to 7 µg/kg) and 5 µg/kg (range, 1 to 10 µg/kg), respectively, for romiplostin. The median platelet count before initiation of TPO-RA therapy was 14,000/µL (range, 1000 to 57,000/µL). Platelet recovery to ≥50,000/µL without transfusion support was achieved in 72% of patients at a median time of 66 days (range, 2 to 247 days). Eighty-one percent of the patients had a decreased number of megakaryocytes before treatment, showing a slower response to therapy (P = .011). The median duration of treatment was 62 days (range, 7 to 700 days). Grade 3-4 adverse events (hepatic and asthenia) were observed in only 2% of the patients. At last follow-up, 81% of patients had discontinued TPO-RAs and maintained response, and 71% were alive. To our knowledge, this is the largest series analyzing the use of TPO-RAs after allo-SCT reported to date. Our results support the efficacy and safety in this new setting. Further prospective trials are needed to increase the level of evidence and to identify predictors of response.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Pirazoles / Trombocitopenia / Trombopoyetina / Benzoatos / Proteínas Recombinantes de Fusión / Receptores Fc / Trasplante de Células Madre Hematopoyéticas / Receptores de Trombopoyetina / Hidrazinas Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male País/Región como asunto: Europa Idioma: En Revista: Biol Blood Marrow Transplant Asunto de la revista: HEMATOLOGIA / TRANSPLANTE Año: 2019 Tipo del documento: Article

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Pirazoles / Trombocitopenia / Trombopoyetina / Benzoatos / Proteínas Recombinantes de Fusión / Receptores Fc / Trasplante de Células Madre Hematopoyéticas / Receptores de Trombopoyetina / Hidrazinas Tipo de estudio: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Adolescent / Adult / Child / Child, preschool / Female / Humans / Infant / Male País/Región como asunto: Europa Idioma: En Revista: Biol Blood Marrow Transplant Asunto de la revista: HEMATOLOGIA / TRANSPLANTE Año: 2019 Tipo del documento: Article